FDA panel gives a thumbs up and a thumbs down to Daiichi cancer drugs

15 May 2019
daiichi-hq

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has voted in favor of approving one cancer drug from Japanese drugmaker Daiichi Sankyo (TYO: 4568) but voted against another one.

There were 12 votes in favor and three against pexidartinib, and if the agency follows the panel’s recommendation, then it will become the first and only approved therapy for tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations, and not amenable to improvement with surgery.

The votes suggest that the benefit outweighs the risks in the treatment of adult patients with symptomatic TGCT, though the FDA will make its final decision by early August, having granted pexidartinib a priority review voucher.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical